

PHARMACY PRE-AUTHORIZATION CRITERIA



DRUG	Natpara (parathyroid hormone)
POLICY #	22141
INDICATIONS	Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
CRITERIA	<p>ConnectiCare considers Natpara to be medically necessary for patients who meet all of the following criteria:</p> <p>Hypocalcemia in adult patients with hypoparathyroidism:</p> <ul style="list-style-type: none">• Must be prescribed by an endocrinologist <p>AND</p> <ul style="list-style-type: none">• Member must have a diagnosis of hypocalcemia secondary to hypoparathyroidism<ul style="list-style-type: none">○ Documented parathyroid levels below the lower limit of normal range, recorded on 2 separate occasions within the past 12 months <p>AND</p> <ul style="list-style-type: none">• Hypocalcemia is not corrected by calcium supplements and active forms of vitamin D alone <p>AND</p> <ul style="list-style-type: none">• Member is currently experiencing symptoms of disease while concurrently taking a calcium supplement and an active form of vitamin D, which are causing intolerable side effects, and member is unable to achieve target serum calcium levels (8-9mg/dL)<ul style="list-style-type: none">○ Lab results with reference ranges must be submitted
LIMITATIONS	<p>Natpara (parathyroid hormone) for injection therapy is not considered medically necessary for members with the following concomitant conditions:</p> <ol style="list-style-type: none">1. Patients with hypoparathyroidism caused by calcium-sensing receptor mutations2. Patients with acute post-surgical hypoparathyroidism. <p>The quantity limit for all strengths of Natpara (parathyroid hormone) for injection is 2 cartridges per 28 days.</p>
REFERENCES	Natpara injection [package insert]. NPS Pharmaceuticals, Bedminster, NJ.
P&T REVIEW HISTORY	8/15, 11/15, 5/16, 5/17, 5/18, 5/19

PHARMACY PRE-AUTHORIZATION CRITERIA

DRUG	Natpara (parathyroid hormone)
REVISION RECORD	2/16